（於中華人民共和國註冊成立的股份有限公司） 股份代號：06660 中 期 報 告 2025 目 錄 | 公司資料 | 2 | | --- | --- | | 管理層討論及分析 | 5 | | 其他資料 | 30 | | 獨立審閱報告 | 41 | | 中期簡明綜合損益及其他全面收益表 | 42 | | 中期簡明綜合財務狀況表 | 43 | | 中期簡明綜合權益變動表 | 45 | | 中期簡明綜合現金流量表 | 46 | | 中期簡明綜合財務資料附註 | 48 | | 釋義 | 62 | 艾美疫苗股份有限公司 二零二五年中期報告 公司資料 執行董事 周延先生 周欣先生 賈紹君先生 關文先生 周杰先生 非執行董事 趙繼臣先生 王愛軍女士 （於2025年4月13日辭任） 獨立非執行董事 Ker Wei PEI教授 文潔女士 郭曉光先生 歐陽輝先生 (於2025年4月13日辭任） 監事 （自2025年5月20日起卸任） 宋廷鋒先生 （監事會主席） 馬倫先生 宋嘉帥先生 審計委員會 Ker Wei PEI教授 （主席） 歐陽輝先生 （於2025年4月13日辭任） 郭曉光先生 文潔女士 （於2025年4月17日獲委任為 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 截至二零二五年六月三十日止 六個月之中期業績公告 中 國 玻 璃 控 股 有 限 公 司（「本公司」）董 事 會（分 別 為「董 事」及「董事會」） 謹 此 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱 為「本集團」）截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 未 經 審 核 綜 合 中 期 業 績，連 同 二 零 二 四 年 同 期 之 比 較 數 字。 1 綜合損益表 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月－未 經 審 核 （以 人 民 幣（「人民幣」）呈 列） | 截至六月三十日止六個月 | 二零二五年 | 二零二四年 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | -- ...

[Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=2&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) The company reported a significant reduction in losses across all key metrics, driven by revenue growth and a shift from gross loss to gross profit Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income Summary | Metric | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 38,872 | 32,449 | +19.8% | | Gross Profit/(Loss) | 2,542 | (3,107) | Turned from loss to profit | | Operating Loss | (19,308) | (124,588) | Loss narrowed by 84.5% | | Loss Before Tax | (37,159) | (126,258) | Loss narrowed by 70.6% | | Loss for the Period | (36,753) | (125,731) | Loss narrowed by 70.8% | | Loss Attributable to Owners of the Company | (32,006) | (79,917) | Loss narrowed by 60.0% | | Basic and Diluted Loss Per Share (HKD) | (0.033) | (0.083) | Loss narrowed by 60.2% | [Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) The company's total assets increased slightly, while current assets decreased and total liabilities rose, leading to a decline in total equity Condensed Consolidated Statement of Financial Position Summary | Metric | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 538,426 | 529,955 | +1.6% | | Total Non-Current Assets | 502,598 | 466,860 | +7.6% | | Total Current Assets | 35,828 | 63,095 | -43.2% | | Total Equity | 211,886 | 242,388 | -12.6% | | Total Liabilities | 326,540 | 287,567 | +13.5% | | Total Non-Current Liabilities | 130,849 | 94,953 | +37.8% | | Total Current Liabilities | 195,691 | 192,614 | +1.6% | - Property, plant and equipment increased to **HKD 248,508 thousand** (December 31, 2024: **HKD 219,341 thousand**), primarily due to additions to construction in progress[5](index=5&type=chunk) - Bank and cash balances decreased to **HKD 11,290 thousand** (December 31, 2024: **HKD 18,913 thousand**), reflecting the use of funds for operations and the construction of the BNCT center[5](index=5&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of the Group's business, accounting policies, and financial performance, highlighting going concern uncertainties and mitigation efforts [1. General Information](index=6&type=section&id=1.%20General%20Information) The company is a GEM-listed entity with diverse healthcare businesses in Hong Kong and mainland China, including medical testing, immunotherapy, and BNCT services - The company's main businesses include medical laboratory testing, health checks, and insurance brokerage services in Hong Kong, as well as oncology immune cell therapy, health management, BNCT services, and sales of healthcare pharmaceutical products in mainland China[7](index=7&type=chunk) - The company is listed on GEM of The Stock Exchange of Hong Kong Limited[8](index=8&type=chunk) [2. Basis of Preparation and Accounting Policies](index=6&type=section&id=2.%20Basis%20of%20Preparation%20and%20Accounting%20Policies) The interim financial information is prepared under HKAS 34, with significant going concern uncertainties due to losses and current liabilities exceeding current assets, addressed by cost control and financing efforts - For the six months ended **June 30, 2025**, the Group recorded a loss of approximately **36,753 thousand HKD**, with current liabilities exceeding current assets by approximately **159,863 thousand HKD**, indicating significant uncertainty about its ability to continue as a going concern[11](index=11&type=chunk) - To alleviate liquidity pressure, the Group is implementing operational plans to control costs, optimize resource allocation, reduce staff costs, and actively seeking alternative financing, borrowings, and fundraising solutions (such as placing shares and issuing convertible bonds)[13](index=13&type=chunk) - The Group is exploring the realization of financial assets measured at fair value through other comprehensive income to support operations and growth[13](index=13&type=chunk) [3. Revenue](index=8&type=section&id=3.%20Revenue) The Group's revenue increased by **19.8%**, primarily driven by a substantial rise in insurance brokerage services, partially offset by a decline in medical laboratory testing and health check services Segment Revenue by Service Category | Service Category | 2025 (HKD thousands) | 2024 (HKD thousands) | Y-o-Y Change (%) | | :--- | :--- | :--- | :--- | | Medical Laboratory Testing and Health Check Services | 16,164 | 19,729 | -18.1% | | Insurance Brokerage Services | 22,640 | 12,255 | +84.7% | | Sales and Distribution of Healthcare-related and Pharmaceutical Products and Other Services | – | 437 | -100% | | Logistics Services | 68 | 28 | +142.9% | | **Total Revenue** | **38,872** | **32,449** | **+19.8%** | [4. Segment Information](index=8&type=section&id=4.%20Segment%20Information) The Group operates six segments, with significant growth in insurance brokerage and BNCT profitability, with capital expenditure focused on BNCT and medical/healthcare and immunotherapy segments remain in loss Segment Revenue and (Loss)/Profit **Segment Revenue (For the six months ended June 30):** | Segment | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Medical Laboratory Testing and Healthcare-related Services | 16,164 | 19,729 | | Insurance Brokerage | 22,640 | 12,255 | | Pharmaceutical Products | – | 437 | | Other | 68 | 28 | | **Total** | **38,872** | **32,449** | **Segment (Loss)/Profit (For the six months ended June 30):** | Segment | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Medical Laboratory Testing and Healthcare-related Services | (14,788) | (71,707) | | Immunotherapy | (13,118) | (25,206) | | Boron Neutron Capture Therapy | 8,776 | (3,147) | | Insurance Brokerage | 1,870 | (62) | | Pharmaceutical Products | (720) | (485) | | Other | (340) | (342) | | **Total** | **(18,320)** | **(100,949)** | - Total capital expenditure in **2025** amounted to **22,700 thousand HKD**, with **22,692 thousand HKD** allocated to Boron Neutron Capture Therapy[21](index=21&type=chunk) - Impairment loss on right-of-use assets in **2025** was **3,524 thousand HKD**[21](index=21&type=chunk) [5. Other Income and Gains/(Losses), Net](index=12&type=section&id=5.%20Other%20Income%20and%20Gains%2F%28Losses%29%2C%20Net) Net other income and gains for the period significantly turned from a loss in **2024** to a gain, primarily due to storm damage compensation and exchange gains Other Income and Gains/(Losses), Net | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Compensation Income | 13,695 | – | | Exchange Gains/(Losses), Net | 6,576 | (12,504) | | Loss on Derecognition of Property, Plant and Equipment | – | (15,901) | | **Total** | **21,728** | **(26,460)** | - Compensation income of **13,695 thousand HKD** relates to insurance claims for storm damage at a Hainan construction site in **2024**[23](index=23&type=chunk) [6. Finance Costs](index=12&type=section&id=6.%20Finance%20Costs) Finance costs substantially increased due to higher interest on convertible bonds, put option liabilities, and other borrowings Finance Costs Breakdown | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest on Bank Borrowings | 523 | 814 | | Interest on Other Borrowings | 4,191 | 1,115 | | Interest on Loans from Controlling Shareholder | 1,291 | 205 | | Interest on Convertible Bonds and Put Option Liabilities | 6,294 | 2,158 | | Interest on Lease Liabilities | 237 | 394 | | **Total** | **12,536** | **4,686** | [7. Loss Before Tax](index=13&type=section&id=7.%20Loss%20Before%20Tax) Loss before tax significantly narrowed, driven by reduced research and development, staff costs, and inventory write-downs, partially offset by impairment loss on right-of-use assets Loss Before Tax Components | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Research and Development Costs | 5,965 | 17,593 | | Staff Costs (Salaries, Bonuses and Allowances) | 25,021 | 38,985 | | Write-down of Inventories | 194 | 5,089 | | Derecognition of Property, Plant and Equipment | – | 15,901 | | Impairment Loss on Right-of-Use Assets | 3,524 | – | [8. Income Tax Credit](index=13&type=section&id=8.%20Income%20Tax%20Credit) Income tax credit for the period was slightly lower than the prior year, primarily derived from deferred income tax Income Tax Credit Breakdown | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Current Income Tax | (195) | (78) | | Deferred Income Tax | 601 | 605 | | **Total** | **406** | **527** | [9. Dividends](index=14&type=section&id=9.%20Dividends) The Board does not recommend any dividend payment for the current interim period, consistent with the prior year - The Board does not recommend the payment of any dividend for the period[27](index=27&type=chunk) [10. Loss Per Share](index=14&type=section&id=10.%20Loss%20Per%20Share) Basic and diluted loss per share attributable to owners of the Company significantly improved, reflecting a reduction in per-share losses Basic and Diluted Loss Per Share | Metric | 2025 (HKD) | 2024 (HKD) | | :--- | :--- | :--- | | Basic and Diluted Loss Per Share | (0.033) | (0.083) | - The weighted average number of ordinary shares used for calculating basic and diluted loss per share increased from **963,231 thousand** in **2024** to **975,731 thousand** in **2025**[29](index=29&type=chunk) [11. Property, Plant and Equipment](index=14&type=section&id=11.%20Property%2C%20Plant%20and%20Equipment) The primary addition to property, plant and equipment for the period was significant investment in construction in progress - Main addition was **22,692 thousand HKD** for construction in progress[30](index=30&type=chunk) [12. Goodwill](index=15&type=section&id=12.%20Goodwill) The carrying amount of goodwill increased, primarily influenced by exchange differences during the period Goodwill Carrying Amount | Metric | June 30, 2025 (HKD thousands) | June 30, 2024 (HKD thousands) | | :--- | :--- | :--- | | Carrying Amount | 107,225 | 104,792 | | Exchange Differences | 3,331 | (2,389) | [13. Intangible Assets](index=15&type=section&id=13.%20Intangible%20Assets) The net carrying amount of intangible assets decreased, mainly due to amortisation expense, partially offset by exchange differences Intangible Assets Net Carrying Amount | Metric | June 30, 2025 (HKD thousands) | June 30, 2024 (HKD thousands) | | :--- | :--- | :--- | | Net Carrying Amount at End of Period | 32,013 | 52,623 | | Amortisation Expense | (4,005) | (4,036) | | Exchange Differences | 1,074 | (985) | [14. Trade and Other Receivables, Deposits and Prepayments](index=16&type=section&id=14.%20Trade%20and%20Other%20Receivables%2C%20Deposits%20and%20Prepayments) Net trade receivables increased, with a significant portion of deposits allocated to purchasing BNCT drugs from a Japanese pharmaceutical company Trade and Other Receivables, Deposits and Prepayments | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Net Trade Receivables | 7,988 | 7,033 | | Rental and Other Deposits | 56,799 | 51,822 | | Other Receivables | 8,246 | 14,012 | | Prepayments | 3,490 | 1,991 | | **Total** | **76,547** | **74,872** | - Rental and other deposits include **54,559 thousand HKD** (equivalent to **1,000,000,000 JPY**) as a deposit paid to a Japanese pharmaceutical company for Boron Neutron Capture Therapy drugs to be used at the Hainan BNCT Cancer Treatment Centre[32](index=32&type=chunk) [15. Trade Payables](index=17&type=section&id=15.%20Trade%20Payables) Total trade payables increased as of **June 30, 2025**, compared to **December 31, 2024** Trade Payables Ageing Analysis | Ageing | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | 0 to 90 days | 4,440 | 4,883 | | 91 to 180 days | 1,278 | 1,549 | | 181 to 365 days | 1,610 | 166 | | Over 365 days | 770 | 755 | | **Total** | **8,098** | **7,353** | [16. Convertible Bonds and Derivative Financial Liabilities](index=17&type=section&id=16.%20Convertible%20Bonds%20and%20Derivative%20Financial%20Liabilities) The Group's convertible bonds and related derivative financial liabilities, including written put option liabilities, saw increases in their fair values - In **December 2024**, convertible bonds with a principal amount of **6,000,000 USD** (approximately **47,100 thousand HKD**) were issued at an annual interest rate of **8.25%** and an initial conversion price of **1.20 HKD** per share[35](index=35&type=chunk) Convertible Bonds and Derivative Financial Liabilities | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Convertible Bonds - Liability Component | 42,919 | 41,635 | | Convertible Bonds - Fair Value of Derivative Component | 11,317 | 6,002 | | Written Put Option Liabilities | 45,065 | 40,480 | - The effective interest rate applied to the convertible bonds' liability component was **15.0%** (**2024**: **8.62%**)[36](index=36&type=chunk) [17. Borrowings](index=19&type=section&id=17.%20Borrowings) Total borrowings increased, primarily for working capital and BNCT center development, secured by various assets, with the Group complying with all financial covenants Total Borrowings and Analysis **Total Borrowings (HKD thousands):** | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Bank Borrowings | 33,981 | 25,981 | | Other Borrowings | 99,041 | 87,940 | | Loans from Controlling Shareholder | 28,074 | 24,772 | | **Total** | **161,096** | **138,693** | **Borrowings Analysis (HKD thousands):** | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Current Portion | 139,179 | 138,693 | | Non-Current Portion | 21,917 | – | - Borrowing interest rates range from **LPR minus 0.45% or 3.45%–3.85%** for bank borrowings, **6%–18%** for other borrowings, and **10%** for controlling shareholder loans[39](index=39&type=chunk) - Borrowings are primarily secured by construction in progress (**233,866 thousand HKD**), China land use rights (**11,799 thousand HKD**), property, plant and equipment (**10,743 thousand HKD**), other receivables (**1,864 thousand HKD**), intangible assets (**30,689 thousand HKD**), and a **47%** equity interest in a subsidiary[40](index=40&type=chunk)[41](index=41&type=chunk) - The Group has complied with the financial covenants of its borrowing facilities[42](index=42&type=chunk) [18. Contingent Liabilities](index=20&type=section&id=18.%20Contingent%20Liabilities) The Group reported no material contingent liabilities as of **June 30, 2025** - The Group had no material contingent liabilities[43](index=43&type=chunk) [19. Related Party Transactions](index=20&type=section&id=19.%20Related%20Party%20Transactions) Related party transactions for the period primarily included interest expenses paid to the controlling shareholder and key management personnel remuneration Related Party Transactions Summary | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest Expenses Paid to Controlling Shareholder | 1,291 | 205 | | Key Management Personnel Remuneration | 2,589 | 3,615 | [20. Events After Reporting Period](index=21&type=section&id=20.%20Events%20After%20Reporting%20Period) Post-reporting period events include a strategic financing agreement where BGI-Songhe will provide a loan to Pengbo (Hainan), convertible into Dynamic Healthcare shares - BGI-Songhe will provide a **30 million RMB** loan to Pengbo (Hainan), which will be converted into shares of Dynamic Healthcare Holdings Limited[46](index=46&type=chunk) - BGI-Songhe will hold up to **6.25%** of Dynamic Healthcare's enlarged issued share capital[46](index=46&type=chunk) [Financial Review](index=22&type=section&id=Financial%20Review) The financial review highlights a significant reduction in net loss, improved gross margin, and reduced operating expenses, despite increased finance costs - Revenue for the period was approximately **38.9 million HKD**, an increase of **19.8%** year-on-year, primarily driven by growth in the insurance brokerage services segment, partially offset by a decline in the medical laboratory testing and health check services segment[48](index=48&type=chunk) - Gross profit turned from a loss of approximately **3.1 million HKD** in the prior year to a profit of approximately **2.5 million HKD**, with gross margin improving to **6.5%**, mainly due to a significant reduction in inventory write-downs[49](index=49&type=chunk) - Selling and distribution expenses decreased by **44.6%** to **3.6 million HKD**, administrative expenses decreased by **52.0%** to **34.0 million HKD**, and research and development costs decreased by **66.1%** to **6.0 million HKD**, primarily due to reduced staff costs, fewer one-off legal claims, and lower late-stage clinical trial expenses[50](index=50&type=chunk)[51](index=51&type=chunk)[52](index=52&type=chunk) - Finance costs increased to **12.5 million HKD**, mainly due to additional bank and other borrowings for working capital and the construction of the BNCT Cancer Treatment Centre[53](index=53&type=chunk) - Net loss attributable to owners of the Company decreased by **60.0%** to **32.0 million HKD**, primarily due to cost control measures, improved gross margin, reduced administrative expenses, and **13.7 million HKD** in insurance compensation income[54](index=54&type=chunk) [Business Review](index=24&type=section&id=Business%20Review) The business review covers strategic financing, progress on the BNCT center, expanded drug cooperation, new insurance products, and advancements in CAR-T clinical trials - Pengbo (Hainan) secured **30 million RMB** in strategic financing from BGI-Songhe to strengthen its development foundation[55](index=55&type=chunk) - The BNCT Cancer Treatment Centre is under construction in Hainan, targeting opening and operation by **end of 2025**, having obtained medical institution practice license and medical device import approval[57](index=57&type=chunk) - Signed an MOU with STELLA PHARMA CORPORATION to expand cooperation for BNCT drug STEBORONINE® in China, including exclusive manufacturing and sales rights, with plans for localized production[58](index=58&type=chunk) - Collaborated with AXA Insurance (Bermuda) Limited to develop comprehensive medical insurance products covering BNCT cancer treatment costs and related services[59](index=59&type=chunk) - Shanghai Longyao's LY007 cell injection (China's first clinically approved CD20-targeted CAR-T therapy) has completed Phase I clinical trials, with Phase II trials planned to commence by **end of 2025**[61](index=61&type=chunk) - Phase I clinical results for LY007 cell injection have been presented at international conferences like ASCO and ASH, and invited for presentation at ICML and EHA[64](index=64&type=chunk) [Outlook](index=27&type=section&id=Outlook) The Group's outlook focuses on laboratory upgrades, expanding healthcare services, commercializing CAR-T products, operationalizing the BNCT center, and developing integrated treatment models and insurance products - The Group has upgraded its laboratory with Hong Kong's first customized virtual biochemistry immunoassay automation system, collaborating with institutions for contract research services and public health screening/vaccination programs[66](index=66&type=chunk) - Demand for health checks and related medical services is expected to continue growing due to increased public health awareness, an aging population, and rising demand for private healthcare services[67](index=67&type=chunk) - The Group aims to advance the commercialization of its CAR-T product LY007 cell injection, pushing for domestic Phase II clinical trials and commercial partnerships, including international patenting, with Phase II trials expected to start by **end of 2025**[68](index=68&type=chunk) - The Group is committed to ensuring the BNCT Cancer Treatment Centre is operational by **end of 2025**, planning a China-wide treatment network, developing franchised hospitals, and generating new revenue from equipment sales and related services[69](index=69&type=chunk) - Deepen industry-academic research integration with leading hospitals to explore a new "diagnosis-treatment integrated" BNCT model[70](index=70&type=chunk) - Strengthen cooperation with insurance companies to develop inclusive BNCT medical insurance products and establish patient referral partnerships with domestic hospitals to enhance accessibility and reduce financial burden[71](index=71&type=chunk) [Events After Reporting Period](index=29&type=section&id=Events%20After%20Reporting%20Period) Details of events after the reporting period are set out in Note 20 to the unaudited condensed consolidated financial statements - Details of events after the reporting period are set out in Note 20 to the unaudited condensed consolidated financial statements[73](index=73&type=chunk) [Liquidity, Financial Resources and Capital Structure](index=30&type=section&id=Liquidity%2C%20Financial%20Resources%20and%20Capital%20Structure) The Group's liquidity shows decreased cash balances and increased borrowings, with capital commitments for property, plant and equipment, and secured loans - Cash and bank balances decreased to **11,290 thousand HKD** (December 31, 2024: **18,913 thousand HKD**), primarily used for operating activities and the construction of the BNCT Cancer Treatment Centre[75](index=75&type=chunk) - Outstanding convertible bonds amounted to approximately **42,919 thousand HKD**, with an annual interest rate of **8.25%**, maturing on **December 27, 2026**[75](index=75&type=chunk) - Total borrowings increased to **161,096 thousand HKD** (December 31, 2024: **138,693 thousand HKD**), mainly due to additional borrowings for working capital and the development of the BNCT Cancer Treatment Centre[76](index=76&type=chunk) Financial Ratios | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Debt-to-Equity Ratio | 60.6% | 54.3% | | Current Ratio | **0.18 times** | **0.33 times** | - Capital commitments for property, plant and equipment increased to **153,210 thousand HKD** (December 31, 2024: **122,560 thousand HKD**)[79](index=79&type=chunk) - Borrowings are secured by Pengbo (Hainan)'s land use rights, construction in progress, property, plant and equipment, other receivables, intangible assets, and equity interest in a subsidiary[80](index=80&type=chunk)[81](index=81&type=chunk) - The Group has no material contingent liabilities and uses hedging instruments to manage foreign exchange and interest rate risks[82](index=82&type=chunk)[83](index=83&type=chunk) [Material Investments Held and Performance](index=33&type=section&id=Material%20Investments%20Held%20and%20Performance) The Group holds significant investments in precision cancer diagnostics companies, with strategic collaborations expected to generate synergies with its medical testing services - The Group holds investments in Pillar Biosciences, Inc and Zhengu Diagnostics Holdings Limited (precision cancer diagnostics companies) with a fair value of approximately **43,703 thousand HKD**, representing **8.12%** of total assets[84](index=84&type=chunk) - Pillar Biosciences, Inc recorded an unaudited loss of approximately **17,000,000 USD** in **2024**, and the Group received no dividend income from Pillar during the period[85](index=85&type=chunk) - Strategic cooperation with Pillar led to the establishment of Asia Molecular Diagnostics Laboratory Limited in Hong Kong, offering next-generation sequencing precision cancer diagnostic services, expected to generate synergies with the Group's medical testing services[85](index=85&type=chunk) [Material Acquisitions and Disposals of Subsidiaries and Associates](index=34&type=section&id=Material%20Acquisitions%20and%20Disposals%20of%20Subsidiaries%20and%20Associates) The Group did not engage in any material acquisitions or disposals of subsidiaries and associates during the reporting period - The Group did not undertake any material acquisitions or disposals of subsidiaries and associates during the period[86](index=86&type=chunk) [Employees and Remuneration Policy](index=34&type=section&id=Employees%20and%20Remuneration%20Policy) The Group's employee count slightly decreased, with remuneration policies based on performance, experience, and market rates, including various benefits and incentive schemes - As of **June 30, 2025**, the Group employed **133** full-time employees (**June 30, 2024**: **142**)[87](index=87&type=chunk) - Remuneration is determined based on performance, experience, and market rates, including discretionary bonuses, MPF scheme, retirement benefit scheme contributions, insurance and medical, training, and participation in share option and share award schemes[87](index=87&type=chunk) [Share Option Scheme](index=34&type=section&id=Share%20Option%20Scheme) The company adopted a share option scheme in **2024**, but no options were granted during the current reporting period - The company adopted a share option scheme on **June 6, 2024**, but no share options were granted during the period[88](index=88&type=chunk) [Share Award Scheme](index=34&type=section&id=Share%20Award%20Scheme) The company adopted a share award scheme in **2021**, but no shares were subscribed for, received, purchased, or granted under the scheme during the current period - The company adopted a share award scheme on **August 18, 2021**, but the trustee neither subscribed for, received, nor purchased any company shares, nor did the company grant any shares under the scheme during the period[89](index=89&type=chunk) [Directors' Rights to Acquire Shares or Debentures](index=35&

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 會 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 SHANDONG GOLD MINING CO., LTD. 山東黃金礦業股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1787） 截 至2025年6月30日止六個月 中期業績公告 2025年中期業績摘要註 註： 一、財務報告（按 照 企 業 會 計 準 則 編 製 的 財 務 報 表） – 1 – 本 公 告 中，除 內 容 特 別 指 明 外，貨 幣 皆 為 人 民 幣。 • 報 告 期 內，本 集 團 實 現 營 業 收 入 人 民 幣56,765.90百 萬 元，同 比 增 長 約 24.01%； • 報 告 期 內，本 集 團 實 現 稅 前 利 潤 人 民 幣5,483.38百 萬 元，同 比 增 長 約 95.23%； • 報 告 期 內，本 集 團 歸 屬 於 母 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 截至二零二五年六月三十日止六個月的 中期業績公告 董事會欣然宣佈本集團於截至二零二五年六月三十日止六個月的未經審核綜 合 中 期 業 績，連 同 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 的 比 較 數 字 如 下。本 集 團於報告期間的未經審核綜合財務報表已由本公司管理層及審核委員會審閱。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至六月三十日止六個月 | | | | | 二零二五年 | 二零二四年 | 同比變動 | | | 人民幣千元 | 人民幣千元 | (%) | | | （未 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 YAN TAT GROUP HOLDINGS LIMITED 恩達集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1480） 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 中 期 業 績 公 告 | 截 | 至 | 截 | 至 | 二 | 零 | 二 | 五 | 年 | 二 | 零 | 二 | 四 | 年 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 （ 於 百 慕 達 註 冊 成 立 的 有 限 公 司 ） （股份代號：613） 二零二五年中期業績（未審核） 於二零二五年六月三十日 梧桐國際發展有限公司（「本公司」）之董事（「董事」）會（「董事會」）公 佈本公司及其附屬公司（統稱「本集團」）截至二零二五年六月三十日止 六個月之未審核綜合業績如下： 簡明綜合損益及其他全面收入表 截至二零二五年六月三十日止六個月 | | | 二零二五年 | 二零二四年 | | --- | --- | --- | --- | | | | 六月三十日 | 十二月三十一日 | | | 附註 | 千港元 | 千港元 | | | | （未審核） | （經審核） | | 非流動資產 | | | | | 物業及設備 | | 28,345 | 33,390 | | 投資物業 | | 340,500 | 407,500 | | 無形資產 | | 12,592 | 12,617 | | ...

[Company Information and Report Overview](index=1&type=section&id=Company%20Information%20and%20Report%20Overview) This section provides an overview of the company, the basis for financial statement preparation, and changes in accounting policies [Company Profile](index=5&type=section&id=General%20Information) Century Legend (Holdings) Limited is an investment holding company with diverse subsidiaries engaged in property investment, hair salons, hospitality, property project management, lending, and securities investment - The company primarily engages in investment holding, with diversified subsidiary businesses including property investment, hair salons, hotels, property project management, lending, and securities investment[8](index=8&type=chunk) [Basis of Preparation](index=5&type=section&id=Basis%20of%20Preparation) The unaudited interim financial statements, reviewed by the Audit Committee, are prepared in accordance with HKFRS and HKAS 34, measured at historical cost, and presented in HKD - The interim financial statements are unaudited but reviewed by the Audit Committee, comply with HKAS 34, and are presented in HKD[9](index=9&type=chunk)[10](index=10&type=chunk) [Changes in Accounting Policies and Estimates](index=6&type=section&id=Adoption%20of%20New%2FRevised%20HKFRSs) The Group adopted amendments to HKAS 21 "Lack of Exchangeability" in 2025, which had no impact on performance or financial position, with significant judgments and estimates remaining consistent with 2024 - Amendments to HKAS 21 adopted in 2025 had no impact on the Group's performance or financial position[11](index=11&type=chunk) - Significant judgments and estimates used in preparing the statements are consistent with those applied in the 2024 annual financial statements[12](index=12&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) This section details the Group's financial results, including comprehensive income, financial position, profit before tax, earnings per share, and key account balances [Condensed Consolidated Statement of Comprehensive Income](index=1&type=section&id=Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) For the six months ended June 30, 2025, the Group achieved a profit of HKD 2,095,000, a significant improvement from the prior year's net loss, primarily due to fair value gains on financial assets Key Data from Condensed Consolidated Statement of Comprehensive Income (Six Months Ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Revenue | 22,151 | 23,767 | | Cost of sales | (15,310) | (15,556) | | Gross profit | 6,841 | 8,211 | | Other income | 366 | 559 | | Fair value gains/(losses) on financial assets at fair value through profit or loss | 16,405 | (11,980) | | Fair value loss on investment properties | (5,800) | (4,000) | | Administrative expenses | (12,967) | (13,998) | | Finance costs | (2,750) | (3,757) | | Profit/(Loss) before income tax | 2,095 | (24,965) | | Income tax credit | – | 384 | | Profit/(Loss) for the period | 2,095 | (24,581) | - Total comprehensive income for the period turned from a loss of **HKD 24,553,000** in the same period of 2024 to a profit of **HKD 2,095,000** in 2025[5](index=5&type=chunk) [Condensed Consolidated Statement of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the Group's total assets slightly increased, non-current assets slightly decreased, while current assets grew, leading to a narrowed net current liabilities and improved net assets and equity attributable to owners Key Data from Condensed Consolidated Statement of Financial Position (As of June 30) | Indicator | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Non-current assets | 309,575 | 315,685 | | Current assets | 70,558 | 64,146 | | Current liabilities | 146,642 | 146,103 | | Net current liabilities | (76,084) | (81,957) | | Net assets | 222,748 | 220,653 | | Equity attributable to owners of the Company | 223,849 | 221,297 | | Total equity | 222,748 | 220,653 | - Net current liabilities narrowed from **HKD 81,957,000** as of December 31, 2024, to **HKD 76,084,000** as of June 30, 2025[7](index=7&type=chunk) [Profit/(Loss) Before Income Tax](index=11&type=section&id=Profit%2F%28Loss%29%20Before%20Income%20Tax) The period's profit before income tax was primarily influenced by a significant increase in fair value gains on financial assets at fair value through profit or loss (HKD 16,405,000), contrasting with a loss in the prior year, alongside a decrease in finance costs Composition of Profit/(Loss) Before Income Tax (Six Months Ended June 30) | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest expense on bank loans | 2,447 | 3,508 | | Interest expense on lease liabilities | 303 | 249 | | Total finance costs | 2,750 | 3,757 | | Fair value (gains)/losses on financial assets at fair value through profit or loss | (16,405) | 11,980 | | Depreciation | 5,582 | 6,207 | - Total finance costs decreased by **26.8%** year-on-year, from **HKD 3,757,000** to **HKD 2,750,000**[22](index=22&type=chunk) [Income Tax Credit](index=11&type=section&id=Income%20Tax%20Credit) The Group had no assessable profit during the reporting period, resulting in no Hong Kong profits tax provision, and no deferred tax assets were recognized due to uncertainty regarding their realization - The Group had no assessable profit during the reporting period, and no Hong Kong profits tax provision was made[23](index=23&type=chunk) - No deferred tax assets were recognized due to uncertainty regarding their realization[23](index=23&type=chunk) [Earnings/(Loss) Per Share](index=11&type=section&id=Earnings%2F%28Loss%29%20Per%20Share%20Attributable%20to%20Owners%20of%20the%20Company) Basic earnings per share attributable to owners of the Company was **0.78 HK cents**, a significant improvement from the prior year's loss of **7.38 HK cents** per share, primarily due to the period's profit Earnings/(Loss) Per Share (Six Months Ended June 30) | Indicator | 2025 | 2024 | | :--- | :--- | :--- | | Basic earnings/(loss) per share | 0.78 HK cents | (7.38) HK cents | | Diluted earnings/(loss) per share | 0.78 HK cents | (7.38) HK cents | - Basic earnings per share turned from a loss of **HKD 24,079,000** in the same period last year to a profit of **HKD 2,552,000** in the current period[25](index=25&type=chunk) [Loans Receivable and Other Receivables, Deposits and Prepayments](index=12&type=section&id=Loans%20Receivable%20and%20Other%20Receivables%2C%20Deposits%20and%20Prepayments) As of June 30, 2025, total loans receivable and other receivables, deposits, and prepayments amounted to **HKD 8,638,000**, slightly lower than **HKD 8,896,000** as of December 31, 2024 Loans Receivable and Other Receivables, Deposits and Prepayments (As of June 30) | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Loans receivable | 1,942 | 2,642 | | Other receivables | 1,676 | 1,304 | | Prepayments | 667 | 601 | | Deposits | 4,353 | 4,349 | | Total | 8,638 | 8,896 | [Trade Payables](index=12&type=section&id=Trade%20Payables) As of June 30, 2025, the Group's total trade payables were **HKD 48,000**, a decrease from **HKD 76,000** as of December 31, 2024 Aging Analysis of Trade Payables (As of June 30) | Aging | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | 0-30 days | 37 | 52 | | 31-60 days | 11 | 20 | | 61-90 days | – | 4 | | Total | 48 | 76 | [Business Review and Segment Information](index=6&type=section&id=Business%20Review%20and%20Segment%20Information) This section reviews the Group's overall performance, macroeconomic environment, and detailed performance across its six operating segments, including revenue, results, assets, liabilities, and geographical information [Overall Performance Review](index=13&type=section&id=Overall%20Performance) The Group's turnover decreased by **7%** to **HKD 22,151,000** and gross profit decreased by **17%** to **HKD 6,841,000** year-on-year, but the period saw a turnaround from net loss to a net profit of **HKD 2,095,000**, driven by fair value gains from securities investments and reduced administrative and finance costs Overall Performance Overview (Six Months Ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Turnover | 22,151 | 23,767 | -7% | | Gross profit | 6,841 | 8,211 | -17% | | Profit/(Loss) for the period | 2,095 | (24,581) | Turned from loss to profit | | Fair value gains/(losses) on financial assets at fair value through profit or loss | 16,405 | (11,980) | Significant improvement | | Reduction in administrative expenses and finance costs | 2,038 | - | - | [Macroeconomic Environment](index=13&type=section&id=Macroeconomic%20Environment) The first half of 2025 presented a challenging global economic landscape with geopolitical tensions and US trade policies impacting the outlook, while Hong Kong and Macau faced retail and real estate challenges, but saw moderate GDP growth and a rebound in Macau's GDP, respectively, with strong securities market performance and declining finance costs - The global economic environment remains challenging, with ongoing geopolitical tensions and impacts from US trade policies[29](index=29&type=chunk) - Hong Kong's GDP grew by **3%** and **3.1%** year-on-year in Q1 and Q2 respectively; Macau's GDP decreased by **1.3%** in Q1 but rebounded to **5.1%** in Q2[29](index=29&type=chunk) - Securities investments showed significant valuation gains, with strong trading volumes in Hong Kong's capital market and outstanding performance in the US stock market[30](index=30&type=chunk) - Finance costs decreased by approximately **27%**, mainly due to the federal funds rate stabilizing from **5.25%-5.5%** to **4.25%-4.5%**[30](index=30&type=chunk) [Revenue and Segment Information](index=6&type=section&id=Revenue%20and%20Segment%20Information) The Group's business is divided into six operating segments: hair salons, hotel and hospitality services, property investment, securities investment, property project management, and lending, with significant variations in revenue and performance, notably the securities investment segment turning from loss to profit and contributing most to overall Group performance - The Group identifies six operating segments: hair salons, hotel and hospitality services, property investment, securities investment, property project management, and lending[14](index=14&type=chunk) [Segment Revenue and Results](index=8&type=section&id=Segment%20Revenue%20and%20Results) The Group's total revenue for the period was **HKD 22,151,000**, a **7%** year-on-year decrease, with the securities investment segment's performance turning from a loss of **HKD 10,544,000** in the prior year to a profit of **HKD 17,431,000**, serving as the primary driver for the Group's overall positive performance Segment Revenue and Results (Six Months Ended June 30) | Segment | 2025 Revenue (HKD thousands) | 2024 Revenue (HKD thousands) | 2025 Results (HKD thousands) | 2024 Results (HKD thousands) | | :--- | :--- | :--- | :--- | :--- | | Hair Salon | 6,174 | 6,520 | 34 | 8 | | Hotel and Hospitality Services | 13,439 | 14,200 | (204) | (547) | | Property Investment | 1,473 | 1,578 | (8,512) | (6,609) | | Securities Investment | 1,027 | 1,428 | 17,431 | (10,544) | | Property Project Management | – | – | (3) | (5) | | Lending | 38 | 41 | (8) | (6) | | Total | 22,151 | 23,767 | 8,738 | (17,703) | - The securities investment segment's performance turned from a loss of **HKD 10,544,000** in the first half of 2024 to a profit of **HKD 17,431,000** in the first half of 2025[15](index=15&type=chunk) [Segment Assets and Liabilities](index=9&type=section&id=Segment%20Assets%20and%20Liabilities) As of June 30, 2025, the Group's total consolidated assets slightly increased to **HKD 380,133,000**, with hotel and hospitality services and property investment segments accounting for a significant portion of assets, while total consolidated liabilities slightly decreased Segment Assets and Liabilities (As of June 30) | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Total segment assets | 372,867 | 369,316 | | Total consolidated assets | 380,133 | 379,831 | | Total segment liabilities | 51,700 | 52,156 | | Total consolidated liabilities | 157,385 | 159,178 | - Assets for the hotel and hospitality services segment were **HKD 226,180,000**, and for the property investment segment were **HKD 85,363,000**, together accounting for the majority of total segment assets[17](index=17&type=chunk) [Other Segment Information](index=10&type=section&id=Other%20Segment%20Information) For the period, total interest income was **HKD 36,000**, fair value loss on investment properties was **HKD 5,800,000**, total finance costs were **HKD 2,750,000**, and total depreciation was **HKD 5,582,000** Other Segment Information (Six Months Ended June 30) | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest income | 36 | 56 | | Fair value loss on investment properties | 5,800 | 4,000 | | Finance costs | 2,750 | 3,757 | | Additions to specified non-current assets | 9 | 64 | | Depreciation | 5,582 | 6,207 | [Geographical Information](index=10&type=section&id=Geographical%20Information) The Group's specified non-current assets are primarily located in Hong Kong (**HKD 235,088,000**) and Macau (**HKD 73,521,000**), with revenue from external customers also mainly derived from Hong Kong (**HKD 20,933,000**) and Macau (**HKD 1,218,000**) Specified Non-Current Assets and Revenue from External Customers (By Geographical Area) | Region | Specified Non-Current Assets as of June 30, 2025 (HKD thousands) | Revenue from External Customers in 2025 (HKD thousands) | | :--- | :--- | :--- | | Hong Kong | 235,088 | 20,933 | | Macau | 73,521 | 1,218 | | Total | 308,609 | 22,151 | [Performance of Each Business Segment](index=14&type=section&id=Performance%20of%20Each%20Business%20Segment) The Group's business segments showed varied performance: property investment saw decreased rental income and valuation losses; hair salon business had lower turnover but increased segment profit; hotel and hospitality services experienced reduced turnover but narrowed losses; securities investment recorded significant fair value gains due to favorable market conditions; property project management had no revenue; and lending business saw slight decreases in interest income and operating loss [Property Investment Business](index=14&type=section&id=Property%20Investment%20Business) The property investment business contributed **HKD 1,473,000** in rental income for the first half, a **7%** year-on-year decrease primarily due to the sale of a Taikoo Shing property, while investment properties in Hong Kong and Macau recorded a valuation loss of **HKD 5,800,000**, with retail shops accounting for approximately **70%** of the loss, and Macau's residential leasing market showing positive performance - Rental income was **HKD 1,473,000**, a **7%** year-on-year decrease, mainly due to the sale of a Taikoo Shing property[31](index=31&type=chunk) - Investment properties recorded a valuation loss of **HKD 5,800,000**, with retail shop losses accounting for approximately **70%**[31](index=31&type=chunk) - Macau's residential leasing market performed positively, with new lease rents increasing by approximately **5%**[33](index=33&type=chunk) [Hair Salon Business](index=15&type=section&id=Hair%20Salon%20Business) The hair salon business generated **HKD 6,174,000** in turnover, a **5%** year-on-year decrease, but segment profit increased to **HKD 34,000**, mainly due to reduced interest expenses and staff long service payment provisions, as the business addresses talent outflow, northbound consumption, and emigration impacts through digital marketing and expanding hair extension and scalp care services Hair Salon Business Performance (Six Months Ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Turnover | 6,174 | 6,520 | | Segment profit | 34 | 8 | - Segment profit increased by approximately **three times** year-on-year, primarily due to reduced revenue, lower interest expenses on right-of-use assets, and decreased provisions for staff long service payments[34](index=34&type=chunk) - Addressing declining turnover through digital marketing, social media promotion, and expanding hair extension and scalp care services[35](index=35&type=chunk)[36](index=36&type=chunk) [Hotel and Hospitality Services Business](index=17&type=section&id=Hotel%20and%20Hospitality%20Services%20Business) The hotel and hospitality services business recorded **HKD 13,439,000** in turnover, a **5%** year-on-year decrease, but net loss narrowed by **63%** to **HKD 204,000**, mainly due to reduced depreciation of right-of-use assets for the North Point hostel, as Hong Kong's tourism recovers amidst challenges of declining average room rates and increased accommodation tax Hotel and Hospitality Services Business Performance (Six Months Ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Turnover | 13,439 | 14,200 | | Net loss | (204) | (547) | - Net loss narrowed by **63%**, primarily due to a significant reduction in depreciation of right-of-use assets for the North Point hostel[38](index=38&type=chunk) - Hong Kong's tourism industry shows strong momentum, receiving approximately **23.6 million** visitors in the first half, a **11.7%** year-on-year increase[39](index=39&type=chunk) - The hotel industry faces challenges of increased occupancy rates but declining average room rates, with the re-imposition of hotel accommodation tax adding cost pressure[40](index=40&type=chunk) [Securities Investment Business](index=18&type=section&id=Securities%20Investment%20Business) As of June 30, 2025, the securities investment business held financial assets of approximately **HKD 53,635,000**, recording a fair value gain of **HKD 16,405,000** for the period, a significant improvement from the prior year's loss of **HKD 11,980,000**, primarily driven by substantial increases in the market value of Hong Kong and US listed securities, with the Group divesting underperforming securities and investing in high-growth US technology and innovation stocks for diversification Key Data from Securities Investment Business (Six Months Ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Fair value gains/(losses) on financial assets at fair value through profit or loss | 16,405 | (11,980) | | Total dividend income from this segment | 1,473 | - | | Fair value of Link Real Estate Investment Trust | 29,377 | - | | Fair value of Palantir Technologies Inc. | 24,084 | - | - The Hong Kong Hang Seng Index rose over **20%** from the beginning of the year, reaching a three-and-a-half-year high, with Hong Kong becoming one of the world's largest IPO markets[43](index=43&type=chunk) - The Group divested some underperforming securities and invested in US stocks in high-growth sectors like technology and innovation to diversify its investment portfolio[43](index=43&type=chunk)[44](index=44&type=chunk) [Property Project Management Business](index=20&type=section&id=Property%20Project%20Business) The property project management business generated no revenue for the period, incurring a segment loss of **HKD 3,000**, with the Group planning to revitalize this business by collaborating with local renowned architects/interior designers to explore new projects - No revenue for the period, with a segment loss of **HKD 3,000**[46](index=46&type=chunk) - Plans to revitalize this business segment by seeking collaborations with local renowned architects/interior designers to explore more new projects[46](index=46&type=chunk) [Other Business Segment (Lending)](index=20&type=section&id=Other%20Business%20Segment) The lending business generated **HKD 38,000** in interest income and incurred an operating loss of **HKD 8,000**, with a new short-term loan initiated and completed during the period, and no impairment recognized on outstanding loans receivable, as the Group adopts a prudent approach to managing its loan portfolio and diversifying credit risk Lending Business Performance (Six Months Ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | | :--- | :--- | :--- | | Interest income | 38 | 41 | | Operating loss | (8) | (6) | - A new short-term loan was initiated and completed during the period, with no impairment recognized on outstanding loans receivable[47](index=47&type=chunk) [Financial Position and Management](index=21&type=section&id=Financial%20Position%20and%20Management) This section covers the Group's liquidity, financial resources, treasury policies, foreign exchange risk, asset pledges, contingent liabilities, capital commitments, material investments, capital structure, and employee remuneration policies [Liquidity and Financial Resources](index=21&type=section&id=Liquidity%20and%20Financial%20Resources) As of June 30, 2025, the Group's cash and bank balances were **HKD 8,417,000**, with net current liabilities of **HKD 76,084,000**, and the current ratio improved to approximately **0.48** from the end of last year Liquidity and Financial Resources (As of June 30) | Indicator | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Cash and bank balances | 8,417 | 12,410 | | Net current liabilities | (76,084) | (81,957) | | Current ratio | 0.48 | 0.44 | - The current ratio improved from **0.44** as of December 31, 2024, to **0.48** as of June 30, 2025, indicating improved liquidity[50](index=50&type=chunk) [Financial Management, Treasury Policy and Foreign Exchange Risk](index=21&type=section&id=Financial%20Management%2C%20Treasury%20Policy%20and%20Foreign%20Exchange%20Risk) There were no significant changes in the Group's financial management, treasury policies, and foreign exchange risk compared to the information disclosed in the 2024 annual report - No significant changes in financial management, treasury policy, and foreign exchange risk compared to the 2024 annual report[51](index=51&type=chunk) [Pledge of Assets](index=21&type=section&id=Pledge%20of%20Assets) During the period, certain investment properties of the Group were pledged to banks to secure bank borrowings of approximately **HKD 118,543,000**, which bear interest at floating rates - Certain investment properties were pledged to banks to secure bank borrowings of approximately **HKD 118,543,000**[52](index=52&type=chunk) [Contingent Liabilities and Capital Commitments](index=21&type=section&id=Contingent%20Liabilities%20and%20Capital%20Commitments) As of June 30, 2025, neither the Company nor the Group had any significant contingent liabilities or material capital commitments - As of June 30, 2025, neither the Company nor the Group had any significant contingent liabilities or capital commitments[53](index=53&type=chunk) [Material Investments](index=22&type=section&id=Material%20Investments) Apart from the securities investments disclosed in this announcement, the Group had no other material investments or future plans for material investments or capital assets as of June 30, 2025 - No other material investments or future plans apart from the disclosed securities investments[54](index=54&type=chunk) [Capital Structure](index=22&type=section&id=The%20Group%27s%20Capital%20Structure) The Group's total equity was **HKD 222,748,000**, with fixed-rate liabilities, floating-rate liabilities, and interest-free liabilities accounting for **5%**, **53%**, and **12%** of total equity, respectively, and the debt-to-asset ratio decreased to approximately **4%** from the end of last year Capital Structure (As of June 30) | Liability Type | Amount (HKD thousands) | Percentage of Total Equity | | :--- | :--- | :--- | | Fixed-rate liabilities | 11,614 | 5% | | Floating-rate liabilities | 118,543 | 53% | | Interest-free liabilities | 27,228 | 12% | | Debt-to-asset ratio | - | 4% | - The debt-to-asset ratio decreased from **5%** as of December 31, 2024, to **4%** as of June 30, 2025[55](index=55&type=chunk) [Employees and Remuneration Policy](index=22&type=section&id=Employees%20and%20Remuneration%20Policy) As of the period end, the Group employed approximately **46** employees, with staff costs of **HKD 6,580,000**, and its remuneration policy is market-competitive, reviewed annually based on employee and Group performance, with a share option scheme available for directors and employees Employee and Remuneration Information (As of June 30) | Indicator | 2025 | 2024 | | :--- | :--- | :--- | | Number of employees | 46 | 48 | | Staff costs (HKD thousands) | 6,580 | 6,453 | - Remuneration policy is market-competitive and determined based on individual employee performance[56](index=56&type=chunk) [Future Outlook](index=23&type=section&id=Future%20Outlook) This section outlines the Group's overall outlook for the remainder of 2025, including specific prospects for the hotel and hospitality services and hair salon businesses, emphasizing continuous improvement, financial strengthening, debt reduction, and strategic asset realization [Overall Outlook](index=23&type=section&id=Outlook%20for%20the%20Remainder%20of%202025) The outlook for the remainder of 2025 is uncertain, influenced by the global economic environment, geopolitical risks, and US trade policies, prompting the Group to continuously improve, strengthen its financial position, explore debt reduction plans, and strategically realize underperforming assets to increase revenue, reduce costs, and enhance efficiency - Future outlook is affected by global economic uncertainty, geopolitical tensions, and US trade policies[57](index=57&type=chunk) - The Group will strengthen its financial position, explore debt reduction plans, and strategically realize underperforming assets to generate cash inflows[57](index=57&type=chunk) [Hotel and Hospitality Services Business Outlook](index=23&type=section&id=Short-Term%20Outlook%20for%20the%20Hotel%20Industry) The short-term outlook for the hotel industry is mixed, but the Group remains cautiously optimistic about the long-term prospects for Hong Kong's tourism and hotel sector, with the HKSAR Government's "Hong Kong Tourism Development Blueprint 2.0" and the opening of Kai Tak Sports Park expected to solidify Hong Kong's position as a world-class tourist destination, offering recovery potential for the Group's mid-range hostels - The Group remains cautiously optimistic about the long-term prospects for Hong Kong's tourism and hotel industry[58](index=58&type=chunk) - The HKSAR Government's "Hong Kong Tourism Development Blueprint 2.0" and the opening of Kai Tak Sports Park are expected to boost tourism development[58](index=58&type=chunk) - The Group's mid-range hostel brands' recognition and customer base are expected to provide resilience and recovery potential[58](index=58&type=chunk) [Hair Salon Business Outlook](index=24&type=section&id=Hair%20Salon%20Business) The hair salon business will continue to focus on customer service standards and seek growth opportunities by understanding customer needs and embracing technological innovation, with AI-driven personalized hair care recommendations and digital consultation platforms expected to reshape the salon experience and enhance customer engagement and retention - The hair salon business will continue to focus on customer service standards and embrace technological innovation[59](index=59&type=chunk) - Introducing technological innovations such as AI-driven personalized hair care recommendations and digital consultation platforms is expected to reshape the salon experience, increasing customer engagement and retention[59](index=59&type=chunk) [Corporate Governance and Others](index=21&type=section&id=Corporate%20Governance%20and%20Others) This section covers the Group's corporate social responsibility initiatives, interim dividend policy, share transactions, corporate governance practices, audit committee review, directors' securities trading, publication of results, and board composition [Corporate Social Responsibility](index=21&type=section&id=Corporate%20Social%20Responsibility) The Group has received the "Caring Company" award for seventeen consecutive years from The Hong Kong Council of Social Service, along with other recognitions like "Good MPF Employer" and "Manpower Developer," demonstrating its firm commitment to social responsibility - Received the "Caring Company" award for **seventeen consecutive years** and multiple other corporate social responsibility recognitions[49](index=49&type=chunk) [Interim Dividend](index=11&type=section&id=Interim%20Dividend) The Directors do not recommend the payment of an interim dividend for the six months ended June 30, 2025 - The Directors do not recommend the payment of an interim dividend for the six months ended June 30, 2025[24](index=24&type=chunk) [Purchase, Sale or Redemption of Listed Securities](index=24&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Listed%20Securities) Neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's shares during the period - Neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's shares during the period[61](index=61&type=chunk) [Corporate Governance](index=24&type=section&id=Corporate%20Governance) The Company generally complied with the Corporate Governance Code in Appendix C1 Part 2 of the Listing Rules during the review period, with the Board believing the combined roles of Chairman and Chief Executive Officer serve the best interests of the Company and its shareholders, and the Audit Committee has reviewed the interim financial statements, with all directors confirming compliance with the standard code for securities transactions [Compliance with Listing Rules Best Practice Guide](index=24&type=section&id=Compliance%20with%20Listing%20Rules%20Best%20Practice%20Guide) The Company generally complied with the Corporate Governance Code, although the roles of Chairman and Chief Executive Officer are held by Mr. Tsang Chiu Wu, an arrangement the Board believes is in the best overall interests of the Company and its shareholders - The Company generally complied with the Corporate Governance Code, but the roles of Chairman and Chief Executive Officer are held by Mr. Tsang Chiu Wu[62](index=62&type=chunk) [Audit Committee and Review of Interim Financial Statements](index=25&type=section&id=Audit%20Committee%20and%20Review%20of%20Interim%20Financial%20Statements) The Audit Committee, comprising all independent non-executive directors, has discussed with management and reviewed the Group's unaudited condensed consolidated financial statements for the six months ended June 30, 2025 - The Audit Committee has reviewed the Group's unaudited condensed consolidated financial statements for the six months ended June 30, 2025[63](index=63&type=chunk) [Standard Code for Directors' Securities Transactions](index=25&type=section&id=Standard%20Code%20for%20Directors%27%20Securities%20Transactions) The Company has adopted the Standard Code as set out in Appendix C3 of the Listing Rules, and all Directors confirmed compliance with this code during the review period - All Directors confirmed compliance with the Standard Code as set out in Appendix C3 of the Listing Rules during the review period[64](index=64&type=chunk) [Publication of Unaudited Interim Results and Interim Report](index=25&type=section&id=Publication%20of%20Unaudited%20Interim%20Results%20and%20Interim%20Report) This interim results announcement has been published on the HKEXnews website and the Company's website, with the interim report to be dispatched to shareholders and made available for inspection in due course - The interim results announcement has been published on the HKEXnews website and the Company's website[65](index=65&type=chunk) [Board of Directors](index=25&type=section&id=Board%20of%20Directors) As of the date of this announcement, the Company's Board of Directors comprises seven directors, including three executive directors (Mr. Tsang Chiu Wu, Ms. Tsang Chiu Wun, and Ms. Chu Ming Tak) and four independent non-executive directors (Mr. Hui Yan Kit, Mr. Lau Pui Wing, Ms. Ho Ting Mei, and Mr. Ng Bun Kuen) - The Board of Directors consists of three executive directors and four independent non-executive directors[66](index=66&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Ye Xing Group Holdings Limited 燁星集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1941） 截至二零二五年六月三十日止六個月 中期業績公告 中期業績摘要 – 1 – • 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月，本 集 團 的 總 收 益 約 為 人 民 幣173.1 百 萬 元，較 二 零 二 四 年 同 期 的 約 人 民 幣186.9百萬元減少約人民幣13.8百 萬元或約7.4%。截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月，物 業 管 理 服 務、 物業開發商相關服務及增值服務產生的收益分別約佔總收益的91.0%、 0.9%及8.1%。 • 物業管理服務分部產生的收益約人民幣157.5百 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 中 國 鐵 路 通 信 信 號 股 份 有 限 公 司 China Railway Signal & Communication Corporation Limited* （在中華人民共和國註冊成立的股份有限公司） （股份代號：3969） 截 至2025年6月30日止六個月之中期業績公告 中 國 鐵 路 通 信 信 號 股 份 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈 本公司及其附屬公司截至2025年6月30日 止 六 個 月 之 未 經 審 計 中 期 業 績。 本 公 告 符 合 香 港 聯 合 交 易 所 有 限 公 司（「香港聯交所」）證 券 上 市 規 則 中 有 關 中 期 業 績 初 步 公 告 附 載 的 資 料 之 要 求。 刊登中期業績公告及中期報告 本業績公告分別在香港聯交所披露易網站(w ...